TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB05321

Activity

Antibacterial Antiviral Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Toxicity and safety peptides

Database_Source

AntiBP3 Peptipedia AI4AVP dbAMP 3.0 DRAVP 2.0 HemoPI Hemolytic2 PD_Hemolysis

Sequence_Type

standard

Has_Modification No

Description A 18-aa standard natural multi-activity (Antibacterial, Antiviral, Hemolysis, and other sources) peptide sequence curated from AntiBP3, Peptipedia, AI4AVP, and other sources, with an available 3D structural model.

Sequence

SWLRDIWDWVCEVLSDFK

FASTA

>TPDB05321|Antibacterial;Antiviral;Hemolysis;Toxicity|length=18
SWLRDIWDWVCEVLSDFK

Formula C108H153N25O29S1

Absent Amino Acids ANQGHMPTY

Common Amino Acids DW

Mass 2297.61

PI 3.97

Basic Residues 2

Acidic Residues 4

Hydrophobic Residues 9

Net Charge -2

Boman Index -0.44

Hydrophobicity -0.050

Aliphatic Index 97.22

Half Life

Mammalian: 1.9 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 16500

Absorbance 280nm 718.14

Polar Residues 3

number

0

A

1

R

0

N

3

D

1

C

1

E

0

Q

0

G

0

H

1

I

2

L

1

K

0

M

1

F

0

P

2

S

0

T

3

W

0

Y

2

V

Amino Acid Distribution

A: 0 R: 1 N: 0 D: 3 C: 1 E: 1 Q: 0 G: 0 H: 0 I: 1 L: 2 K: 1 M: 0 F: 1 P: 0 S: 2 T: 0 W: 3 Y: 0 V: 2

Length

18

Formula

C108H153N25O29S1

Mass

2297.61

PI

3.97

Net Charge

-2

Boman Index

-0.44

Hydrophobicity

-0.050

Evidence 1 Activity

Activity

Activity Endpoint MHC

Detail Source Activity Hemolysis

Activity Measurement 13.93 µM

Hemolysis Raw

[Ref.21801309]Human erythrocytes:MHC=13.93 µM.

Target

RBC Target Human erythrocytes

Source & Reference

Database Source Hemolytik PD_Hemolysis

Source DRAMP4

Reference

Chem Biol Drug Des. 2011 Nov 78(5):835-43.

Other

Source Activity Label	Source Definition
Hemolysis	Hemolytik experimentally validated hemolytic peptide annotation.

Evidence 2 Activity

Activity

Activity Endpoint 0% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 13.93 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

0% Hemolysis | 13.93 | µM | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Rational design of peptides with anti-HCV/HIV activities and enhanced specificity. | Chem Biol Drug Des | 2011

Evidence 3 Activity

Activity

Activity Endpoint MHC

Detail Source Activity Toxicity

Activity Measurement 13.93 µM

Toxicity Type Hemolytic

Toxicity Raw

Hemolytic_activity: [Ref.21801309]Human erythrocytes:MHC=13.93 µM.

Target

Target Cell erythrocytes

Source & Reference

Database Source NA

Source Database DRAMP

Reference

Chem Biol Drug Des. 2011 Nov 78(5):835-43.

Evidence 4 Hemolysis

Activity

Activity Measurement 13.93 µM

Activity Endpoint MHC

Hemolysis Raw

[Ref.21801309]Human erythrocytes:MHC=13.93 µM.

Detail Source Activity Hemolysis

Target

RBC Target Human erythrocytes

Source & Reference

source HemoPI PD_Hemolysis

Reference

Chem Biol Drug Des. 2011 Nov 78(5):835-43.

Source DRAMP4

Database Source PD_Hemolysis